摘要食管癌患者约40%在初次诊断时就已出现转移。尽管免疫治疗改变了晚期、复发或转移性食管癌的治疗格局，但系统性治疗的手段仍然有限，预后欠佳。寡转移被认为是介于局部转移和广泛转移的中间阶段。有研究显示，在系统性治疗的基础上联合放疗等局部治疗可能改善多种实体瘤中寡转移患者的生存，包括食管癌寡转移。目前关于食管癌寡转移放射治疗的介入时机、剂量、技术等问题，仍缺乏大型随机临床试验的数据支持。综合近年来食管癌寡转移研究的数据，中国医师协会放射肿瘤治疗医师分会、中华医学会放射肿瘤治疗学分会、中国抗癌协会肿瘤放射治疗专业委员会、中国肿瘤放射治疗联盟食管癌专家委员会组织专家组成员，经过深入讨论、多次修改，共同制定了该共识。针对食管癌寡转移进行了较为明确的定义及分类，并基于当前的医学证据对放疗常见问题进行梳理总结，以期为食管癌寡转移放射治疗临床实践提供参考及学术性指导意见。

abstractsApproximately 40% of esophageal cancer patients have metastatic disease at the time of initial diagnosis. Although immunotherapy has changed the treatment pattern of advanced, recurrent or metastatic esophageal cancer, the options for systemic treatment for these patients are still limited, and the prognosis is poor. Oligometastasis is an intermediate stage between locoregional and widespread systemic metastasis. Some studies have shown that combining systemic treatment with local treatment, such as radiotherapy, may improve the survival of patients with oligometastasis in various solid tumors, including esophageal cancer. At present, there is still a lack of data support from large randomized clinical trials on the timing, dose, and technique of radiotherapy for oligometastatic esophageal cancer. Based on recent studies on oligometastatic esophageal cancer, this consensus was jointly developed after in-depth discussions and multiple revisions by experts from the following organizations: Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association; Branch of Radiation Oncology Therapy, Chinese Medical Association; Professional Committee of Radiotherapy for Cancer, Chinese Anti-cancer Association; Expert Committee of Esophageal Cancer, Chinese Radiation Therapy Oncology Group. This consensus provides a relatively clear definition and classification of oligometastatic esophageal cancer. It summarizes common problems in radiotherapy based on current medical evidence, to provide reference and academic guidance for the clinical practice of radiotherapy for oligometastatic esophageal cancer.